Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 in Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT01910025Phase 2Completed
- Sponsor
- Polaris Group
- Start
- Dec 2013
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Pegargiminase in Non-Hodgkin lymphoma (NHL), sponsored by Polaris Group. Started Dec 2013; status: completed.
02
Drugs
Pegargiminase
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01910025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01910025.